| [1] |
Sung H, Ferlay J, Siegel R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
|
| [2] |
张琴琴, 黄怡, 陆光远, 等. 新辅助化疗药物对乳腺癌疗效预测相关生物标志物影响的研究进展 [J]. 中国药房, 2020, 31(16): 2033-2037.
|
| [3] |
Jaeger B, Neugebauer J, Andergassen U, et al. The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial[J]. PLoS One, 2017, 12(6): e0173593.
|
| [4] |
Jhaveri K, Wang R, Teplinsky E, et al. A phase Ⅰ trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer[J]. Breast Cancer Res, 2017, 19(1): 89.
|
| [5] |
Tommasi C, Pellegrino B, Diana A, et al. The innate immune microenvironment in metastatic breast cancer [J]. J Clin Med, 2022, 11(20): 5986.
|
| [6] |
Rana RS, Naik B, Yadav M, et al. Serum complements and immunoglobulin profiles in systemic lupus erythematosus patients: An observational study at a teaching hospital[J]. J Family Med Prim Care, 2022, 11(2): 608-613.
|
| [7] |
Wu X, Lin L, Cui J, et al. Complement C3 deficiency ameliorates aging related changes in the kidney[J]. Life Sci, 2020, 260: 118370.
|
| [8] |
Li Q, Lu Q, Zhu MQ, et al. Lower level of complement component C3 and C3a in the plasma means poor outcome in the patients with hepatitis B virus related acute-on-chronic liver failure[J]. BMC Gastroenterol, 2020, 20(1): 106.
|
| [9] |
Macor P, Capolla S, Tedesco F. Complement as a biological tool to control tumor growth [J]. Front Immunol, 2018, 9: 2203.
|
| [10] |
路平, 魏少忠, 梁新军. 补体系统与肿瘤免疫的研究进展[J].中国肿瘤临床, 2021, 48(13): 681-685.
|
| [11] |
Li Y, Miao W, He D, et al. Recent progress on immunotherapy for breast cancer: tumor microenvironment, nanotechnology and more[J]. Front Bioeng Biotechnol, 2021, 9: 680315.
|
| [12] |
Vaziri Fard E, Ali Y, Wang XI, et al. Tumor-infiltrating lymphocyte volume is a better predictor of disease-free survival than stromal tumor-infiltrating lymphocytes in invasive breast carcinoma[J]. Am J Clin Pathol, 2019, 152(5): 656-665.
|
| [13] |
Lee H, Lee M, Seo JH, et al. Changes in tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and clinical significance in triple negative breast cancer [J]. Anticancer Res, 2020, 40(4): 1883-1890.
|
| [14] |
梁奋莉, 曹培龙, 曹伟, 等. 肿瘤浸润淋巴细胞对不同分子亚型乳腺癌预后效应的研究进展[J]. 现代肿瘤医学, 2020, 28(16): 2894-2897.
|
| [15] |
Tsang JY, Hui SW, Ni YB, et al. Lymphocytic infiltrate is associated with favorable biomarkers profile in HER2-overexpressing breast cancers and adverse biomarker profile in ER-positive breast cancers[J]. Breast Cancer Res Treat, 2014, 143(1): 1-9.
|
| [16] |
Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: A pooled analysis of 3 771 patients treated with neoadjuvant therapy[J]. Lancet Oncol, 2018, 19(1): 40-50.
|
| [17] |
Miyoshi Y, Shien T, Ogiya A, et al. Associations in tumor infiltrating lymphocytes between clinicopathological factors and clinical outcomes in estrogen receptor-positive/human epidermal growth factor receptor type 2 negative breast cancer[J]. Oncol Lett, 2019, 17(2): 2177-2186.
|
| [18] |
Herbert A. Complement controls the immune synapse and tumors control complement[J]. J Immunother Cancer, 2020, 8(2): e001712.
|
| [19] |
Fan Z, Qin J, Wang D, et al. Complement C3a promotes proliferation, migration and stemness in cutaneous squamous cell carcinoma[J]. J Cell Mol Med, 2019, 23(5): 3097-3107.
|
| [20] |
Gadwa J, Bickett TE, Darragh LB, et al. Complement C3a and C5a receptor blockade modulates regulatory T cell conversion in head and neck cancer[J]. J Immunother Cancer, 2021, 9(3): e002585.
|
| [21] |
Roumenina LT, Daugan MV, Petitprez F, et al. Context-dependent roles of complement in cancer[J]. Nat Rev Cancer, 2019, 19(12): 698-715.
|
| [22] |
昝琦, 刘欣, 逄越, 等. 补体C3结构与功能研究进展[J]. 中国免疫学杂志, 2014, 30(4): 549-553.
|